Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

First patient treated with ILB in TIKOMED’s clinical trial for ALS

Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden. Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well underway and that

HIDDN: Receives initial order from ALSO

(Oslo, 2 November 2018) Hiddn Solutions ASA (Hiddn, OSE: HIDDN) has received the first order from ALSO Holding AG (ALSO). The initial order has a value of NOK 1.7 million and covers Hiddn’s KryptoDisk and other encryption products for the Scandinavian market. The products will be available for purchase from ALSO during the fourth quarter of 2018. “We are pleased to receive this first order from ALSO under our agreement signed in late June 2018. This first order confirms the demand for Hiddn's GDPR compliant secure data storage solutions in Scandinavia and is a stepping stone into

Selvaag Bolig ASA: Notice of annual general meeting

An extraordinary general meeting of Selvaag Bolig ASA will be held on 23 November 2018 at 12:00 (CET) at Silurveien 2, 0311 Oslo, Norway.Notice attached.Further information fromKristoffer Gregersen, Vice president communications and market Selvaag Bolig ASATelephone: +47 957 75 593, e-mail: kgr@selvaagbolig.noSelvaag Bolig ASA is a residential property developer controlling the entire value chain from acquisition of land to sale of homes. The company has several thousand homes under development at any given time, and focuses on the growth areas in and around Greater Oslo, Bergen,

Redeye: Idogen - Preparations and capital raise on the agenda

Idogen continues the preparations to get their IDO projects into clinic. To finance the push, a SEK 60 million equity raise has been announced. With this report we provide an update on our take on the case. Read more and download research update: http://bit.ly/2SEftX8 Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Invitation to the presentation of Edgeware’s third quarter report 2018

Edgeware's report for the third quarter 2018 will be published at 07:30 CET on November 9A web-cast telephone conference will be held at 10:00 CET the same day, where CEO Karl Thedéen and CFO Steeve Fuhr will present the report. The presentation will be followed by a Q&A session.  The presentation will be held in English and can be followed on the web or over the phone. To participate in the conference call, call one of the following numbers: SE: +46856642662 UK: +442030089802 US: +18557532235  You can follow and listen to the presentation on the following page:   https:

Nordic Nanovector ASA: Invitation to Third Quarter 2018 Results Presentation and Webcast

Oslo, Norway, 2 November 2018 Nordic Nanovector ASA (OSE: NANO) will announce its third quarter 2018 results on Tuesday, 6 November 2018. A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CET on 6 November at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: HOLMENKOLLEN The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/

Lehto Group Plc: Business Review January-September 2018

Lehto Group PlcStock Exchange Release2 November 2018 at 8.04 a.m.LEHTO GROUP PLC BUSINESS REVIEW, 1 JANUARY–30 SEPTEMBER 2018  January–September net sales up by 46.1%,operating profit 4.5% of net sales  This is not an interim report as specified in the IAS 34 standard. The company complies with half-yearly reporting according to the Finnish Securities Markets Act and discloses business reviews for the first three and nine month periods of the year, in which key information regarding the company's financial situation and development will be presented.   The financial

Lehto Group Plc: Change in Lehto’s Group Executive Board

Lehto Group PlcStock exchange release2 November 2018 at 8:02 a.m.There will be a change in Lehto Group’s executive board as of 5 November 2018. Pekka Lindeman, Executive Vice President of Building Renovation service area, will not continue as a member of Group Executive Board. The change is due to the reorganisation of Building Renovation service area which Lehto informed by stock exchange release on 2 November 2018. The executive board of Lehto Group Plc at November 5, 2018 consist of: Hannu Lehto, CEO Veli-Pekka Paloranta, Chief Financial Officer Pasi Kokko, Executive Vice

IK Investment Partners to support SCHEMA Group

IK Investment Partners (“IK”) is pleased to announce that the IK Small Cap II Fund together with the founders has reached an agreement to acquire SCHEMA Group (“SCHEMA” or “the Company”), a leading developer and provider of software solutions for demanding product- and process-related content. Financial terms of the transaction are not disclosed, and the completion of the transaction is subject to regulatory approval.Founded in 1995 by Marcus Kesseler and Stefan Freisler, SCHEMA provides sophisticated component content management system (CCMS) software for creating modular documentation in

Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® plus Rituximab in Follicular Lymphoma

Oslo, Norway, 2 November 2018 Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). Rituximab is a CD20-targeting monoclonal antibody that is administered to patients with newly-diagnosed or relapsed FL as a single agent or in combination with chemotherapy. Over time, patients may develop resistance to RTX, thus alternative targets are important. In addition, developing novel “chemo-free” regimens for

BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC

· Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC · Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC · Stage 2 open and enrollingBergen, Norway, 2 November 2018 - BerGenBio ASA (OSE:BGBIO) announces that the analysis of the first stage of its Phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been

Lehto Group Plc: Lehto reorganises its building renovation operations

Lehto Group PlcStock Exchange Release2 November 2018 at 8.00 a.m.Lehto has two units in Building Renovation service area; a pipeline renovation unit focusing on plumbing rebuilding of blocks of flats, and complete renovation unit which focuses on comprehensive renovation and complementary construction projects (in which additional floors are built on top of existing buildings). The pipeline renovation unit represents approximately one third of the net sales of the entire service area's net sales and its projects are progressing as planned. In the complete renovation unit, the projects

Archer Limited: Third quarter 2018 - Best quarterly operating result in 3 years

Hamilton, Bermuda (November 2, 2018) Third Quarter 2018 earnings release highlights ·  Best quarterly operating result in 3 years.  ·  Revenue of $213.7 million.  ·  EBITDA before exceptional items of $25.7 million, an increase of 45% from same quarter last year.  ·  EBITDA of $22.4 million, an increase of 75% from same quarter last year.   ·  EBIT of $8.6 million  ·  Divestment of US Onshore (AWC Frac Valves) for $30 million.  ·  All geographies and segments reported positive EBITDA, including within Land Drilling.  John Lechner, CEO Archer comments: “Archer

SDRL - Q3 2018 earnings release date and conference call information

London, United Kingdom, November 2, 2018 - Seadrill Limited is scheduled to release its third quarter 2018 results on Tuesday November 27[th], 2018.A conference call and webcast will be held at 10:30 a.m. EST / 3:30 p.m. GMT on Tuesday November 27[th], 2018.To listen to the management presentation of the results, the following options are available:A. WebcastIn order to register to listen to the conference call, please click this link. B. Conference callParticipants can register for the conference call and receive

SDLP - Q3 2018 earnings release date and conference call information

London, United Kingdom, November 2, 2018 - Seadrill Partners LLC is scheduled to release its third quarter 2018 results on Tuesday November 20[th], 2018.A conference call and webcast will be held at 10:30 a.m. EST / 3:30 p.m. GMT on Tuesday November 20[th], 2018.To listen to the management presentation of the results, the following options are available:A. WebcastIn order to register to listen to the conference call, please click this link. B. Conference callParticipants can register for the conference call and

BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease

Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie (NYSE: ABBV) and BioArctic. The option is subject to filing and clearance under the US Antitrust legislation. BioArctic and AbbVie, a global biopharmaceutical company, in 2016 entered into a strategically important collaboration to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein

Ocean Yield Q3 2018 Presentation

Please find attached the Q3 2018 presentation to be held tomorrow, Friday 2nd November 2018. Presentation · Time: 09:00 CET, Friday 2nd November 2018 · Location: The Thief, Tjuvholmen, Oslo, Norway · Webcast: http://webtv.hegnar.no/presentation.php?webcastId=97451409 · PDF link: Ocean Yield Q3 2018 Presentation  · Webpage: https://www.oceanyield.no/Investor-Relations This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Getinge clarifies FDA communication to health care providers

Following the media coverage relating to the FDA communication to health care providers Getinge would like to make the following clarification.On November 1, 2018, the American Food and Drug Administration (FDA) posted a Health Care Provider letter on the FDA Website regarding post market safety concerns with Maquet/Getinge ballonpump products. Getinge would like to clarify that FDA is evaluating recent medical device reports (MDR) of ballonpumps shutting down while running on battery power. The communication from FDA today is part of a normal process to inform health care facilities and

Ocean Yield ASA: Third Quarter results 2018

Fornebu, 1st November 2018, Ocean Yield ASA (“Ocean Yield” or the “Company”) announces results for the third quarter ending 30th September 2018. Highlights Q3 2018 · Declared a dividend of USD 0.1910 per share for Q3 2018. This is the 21st consecutive quarterly dividend since the IPO of the Company in 2013. · EBITDA for Q3 2018 was USD 85.1 million and EBITDA adjusted for finance lease effects was USD 100.4 million. · Net profit after tax was USD 39.9 million and Adjusted net profit was USD 37.3 million. · Delivery of two Suezmax tankers with 10-year charters to Nordic

Rights Issue resolved by the extraordinary general meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES (OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL). THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.The extraordinary general meeting in Nordic Mining ASA (the "Company") was held today, Thursday 1 November 2018. All items for consideration were approved. The minutes of the extraordinary general meeting is enclosed to this notice in Norwegian and in English translation.

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 01.11.2018

Fiskars Corporation  NOTIFICATION 01.11.2018 at 18:30 EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 01.11.2018 Date 01.11.2018Exchange transaction BuyShare class FSKRSAmount       1 500 Average price/share 16.2742  EUR  Highest price/share 16.3000 EUR Lowest price/share 16.1800 EUR Total price 24,411.30  EUR  The shares held by Fiskars Corporation on 01.11.2018: FSKRS 279,805  On behalf of Fiskars Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka   Janne Tiihonen

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 01.11.2018

United Bankers Corporation NOTIFICATION 01.11.2018 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 01.11.2018          Date 01.11.2018Exchange transaction BuyShare class UNIAVAmount 904Average price/share 7.3000 EURHighest price/share 7.3000 EURLowest price/share 7.3000 EURTotal price 6 599.20 EUR The shares held by United Bankers Corporation on 01.11.2018: UNIAV 69,279 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ) Antti

There are no items matching the current filter
There are no more items matching the current filter
Back to top